Our Core Purpose
To improve the lives of patients by creating and developing innovative antibody products.
Our Core Values
Passion for innovation
Work as one team and respect each other
Determined - being the best at what we do
Integrity - we do the right thing
Our Strategy
- Focus on the core competence of identifying the best disease targets and developing unique best-in-class or first-in-class antibodies, and be at the leading edge in developing next generation technologies
- Turn science into medicine by producing innovative antibodies with significant commercial potential and that make business sense
- Build a profitable and successful biotech by maintaining a flexible and capital efficient model by maximizing partnership relationships
To achieve these strategic aims the company will focus on the dominant priorities, act in a disciplined manner and balance scientific, medical and business factors to advance products through its pipeline.
Our Team
The Genmab team is comprised of highly skilled and experienced professionals with the dedication, determination and integrity necessary to succeed in the competitive biotechnology industry. Our international teams work closely together to streamline and coordinate product discovery, manufacturing, pre-clinical testing, clinical trial design, data management and regulatory submissions.
Our Product Pipeline
Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential cancer treatment. Our pipeline of fully human antibodies currently consists of 4 products in clinical development as well as numerous pre-clinical programs and other disease targets under exploration. Detailed information on our products can be found on our
Products in Development page.
Our Technology
Using the HuMAb-Mouse® transgenic mouse technology licensed from Medarex, a wholly owned subsidiary of Bristol-Myers Squibb, Genmab can rapidly create fully human high affinity antibodies which may have less potential to elicit allergic responses or other side effects than previous generations of antibody products which have typically contained mouse or other animal proteins. The HuMAb-Mouse technology, furthermore, eliminates the need for humanization or complicated genetic engineering, which can be time consuming and expensive.
In 2010, Genmab announced DuoBody™, a novel next generation bispecific antibody technology. Bispecific antibodies combine the ability to bind two targets in a single molecule. This may result in more precise targeting and increased efficiency of disease killing mechanisms. Previous generations of bispecific technologies suffered from manufacturing difficulties and/or instability of bispecific molecules and also only remained in the body for a very short period of time. Genmab’s novel proprietary bispecific antibody technology results in efficient generation of the desired type of bispecific antibodies. The new bispecific antibodies are human, stable and may remain in the body as long as regular human antibodies, giving the new bispecific antibodies more time to attack disease.
In addition, Genmab has developed UniBody®, a proprietary technology which is used to create a smaller antibody format which may offer several advantages over traditional full size monoclonal antibodies. The UniBody's small size means it has better distribution over targeted areas . The UniBody also binds to only one site and does not produce an immune response, making it possible to treat some forms of inflammation and asthma that other antibodies cannot treat.
Our Development Capabilities
Genmab's pre-clinical development team works diligently to select the best antibody candidates for development. A panel of antibodies is generated and put through a rigorous series of laboratory functional assays designed to identify the characteristics of the best therapeutic product. Following this in vitro testing, the product candidate is evaluated in vivo using animal disease models prior to initiation human clinical trials. Our in house regulatory, clinical development and data management teams then use their international expertise to move Genmab's products through the clinic.